This article was originally published on TipRanks.com AbbVie (NYSE: ABBV) has received U.
This article was originally published on TipRanks.com AbbVie, Inc.
This article was originally published on TipRanks.com.
This article was originally published on TipRanks.com Biopharmaceutical company AbbVie (ABBV) updated the U.
AbbVie (ABBV) has received the European Commission’s (EC) approval for interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab) to be used separately or with methotrexate (MTX) …
AbbVie (ABBV) has presented integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2. These studies are designed to evaluate the efficacy and safety of risankizumab (SKYRIZI) in adult …
Biopharmaceutical company AbbVie (ABBV) provided upbeat guidance for 2021 after it posted better-than-expected earnings for the third quarter of 2021 on Friday. The …
Shares of AbbVie (ABBV) rose 1.2% to close at $109.
AbbVie’s (ABBV) Allergan Aesthetics is to acquire Soliton (SOLY) plus its Rapid Acoustic Pulse device, which was recently approved by the U.S.
AbbVie (ABBV) is off to a good start going by its impressive 1Q 2021 results. Net revenues increased by 51% year-over-year to $13.